|
HCT-116 derived colon-carcinoma microtissues
Origin
hCo-CCL01MT microtissues are formed by HCT-116 human colon carcinoma cells. This cell line was established from a primary colon carcinoma and was described to be tumorgenic in nude mice (Brattain MG et al., 1981, Cancer Res.). The HCT-116 cells were obtained from DSMZ (German Collection of Microorganisms and Cell Cultures).
From 2D to 3D. Microtissue formation and growth
HCT-116 cells from a monolayer culture were trypsinized and 500 cells were seeded per microtissue. Pictures were taken of the monolayer culture (2D) and of the microtissues at day 1, 4 and 7 after seeding.
Microtissue growth and drug sensitivity
(A) HCT-116 cells from a monolayer culture were trypsinized and 500 cells were seeded per drop. Microtissue size and ATP content were measured at day 3, 5, 7 and 10 after inoculation. (B) Microtissues at day 4 were treated for 3 days with indicated concentrations of taxol (0.1% DMSO). ATP content was measured as a viability indicator and normalized to the DMSO only treated control.
Histological Analysis
hCo-CCL01MT were fixed and embedded into paraffin blocks at day 6 after seeding. Paraffin sections were stained with H&E (A) and for Ki67 (B).
Specification
|
| Microtissue type |
Colon cancer cell line (HCT-116 derived) microtissue |
| MT growth medium |
RPMI + supplements
|
| Delivery format |
non-adhesive 96-well V-bottom plate, room temp. |
| Initial cell number per microtissue |
1000 |
| Microtissue growth prior delivery |
4-6 days |
| Microtissue size upon delivery |
300-400 μm in diameter |
| Tissue growth rate |
fast |
| Mycoplasm |
negative in MycoAlert assay |
| Viruses (tested by cell supplier) |
ELISA: reverse transcriptase negative;
PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV -, HTLV-I/II -, SMRV - |
|
